{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chronic-obstructive-pulmonary-disease/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"8f4eeb38-3744-5824-a90c-82b0b8906580","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 9765f0bb-6092-42a2-b130-13824be084fa --><h2>Changes</h2><!-- end field 9765f0bb-6092-42a2-b130-13824be084fa -->","summary":null,"htmlStringContent":"<!-- begin item 1eee9984-2137-4848-b60e-c1514437d914 --><!-- begin field 89d3fa4c-7e90-4633-8eb1-96728a869cc0 --><p><strong>October 2020 </strong>— minor update. The initial dose of azithromycin to be used in people starting prophylactic macrolide therapy has been added to this topic. </p><p><strong>August 2020 </strong>— minor update. A typographical error has been corrected.</p><p><strong>April 2020</strong> — minor update. The topic has been updated to take into account the latest BTS guideline on macrolide use.</p><p><strong>April 2020</strong> — minor update. New management scenario created to provide information regarding COVID-19.</p><p><strong>September to November 2019 </strong>— reviewed. A literature search was conducted in August 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic.</p><!-- end field 89d3fa4c-7e90-4633-8eb1-96728a869cc0 --><!-- end item 1eee9984-2137-4848-b60e-c1514437d914 -->","topic":{"id":"8e2a563d-c3b1-5ed5-a460-de2b3ffc8c0f","topicId":"e48489e8-63d1-4a04-bc5b-07e36a76af58","topicName":"Chronic obstructive pulmonary disease","slug":"chronic-obstructive-pulmonary-disease","lastRevised":"Last revised in October 2020","chapters":[{"id":"8441dfb8-d2f6-511c-abf6-23d0c8a600d0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5ccd2981-1bc9-5357-86d2-cbf578b57adb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2eb66d0c-0e3f-55c2-bb2f-ba47fdbd1bfd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8f4eeb38-3744-5824-a90c-82b0b8906580","slug":"changes","fullItemName":"Changes"},{"id":"f2cfeec1-2d2a-5d22-b569-42eb61ba7caa","slug":"update","fullItemName":"Update"}]},{"id":"d28cbe2c-ffc9-58ab-913c-3afa52c28841","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"99f07881-2c1a-5874-8cd2-3f10dcb385fa","slug":"goals","fullItemName":"Goals"},{"id":"85c2e06f-fe1e-532b-8752-0337ca19cfe3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f6fa4f07-a45d-5c3e-8c59-2054ea5ecd38","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"defe1786-7b6d-5c90-a7f4-0871262dd84f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e6356570-e32f-5480-89d6-026b80bb055d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0433c46f-8e2f-53b3-a392-aca635b35160","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"29a2fdef-c0c3-5bb6-9c12-21d649ed27bb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"715af617-76e1-5846-9262-1616f0003270","slug":"definition","fullItemName":"Definition"},{"id":"6f383baf-ff39-58db-b933-24b4c5feb5f8","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"7fe9ff8f-68ba-5f97-91ab-8d23c907b1cf","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4bcdbaec-2487-5733-812a-7ec514939f8d","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c7c94e20-91a7-5b3d-b8dd-0d4f8d5c023c","slug":"complications","fullItemName":"Complications"}]},{"id":"844f6e5f-bd6a-5d1d-8f3e-0980e52cd744","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"aa2453ae-c791-521b-9ead-ca40d5efae00","slug":"diagnosis-copd","fullItemName":"Diagnosis - COPD"},{"id":"93fac9cc-fc19-5440-8330-f6f56941ddb6","slug":"diagnosis-acute-exacerbation","fullItemName":"Diagnosis - acute exacerbation"}]},{"id":"b513a018-d7cf-53a1-9748-c7fa367312d0","fullItemName":"Management","slug":"management","subChapters":[{"id":"4aafe1b6-b17a-51d8-a8f0-104880ac3722","slug":"stable-copd","fullItemName":"Scenario: Stable COPD"},{"id":"ef02510d-99b8-561a-b40c-8bfaab787b88","slug":"acute-exacerbation","fullItemName":"Scenario: Acute exacerbation"},{"id":"22cd95c6-b76a-5e58-8329-cfed9e9bf26e","slug":"end-stage-copd","fullItemName":"Scenario: End-stage COPD"},{"id":"f1d4be42-b98a-55de-860a-3be931c97c1c","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"6e9178ad-4f96-5153-b348-f5f0f9132463","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"651db25c-bc72-5eaa-b790-e5c86053d13c","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"51f6354b-2f19-59ca-889c-a9497e0223fc","slug":"muscarinic-antagonists","fullItemName":"Muscarinic antagonists"},{"id":"10bec3db-4371-5d92-a5e9-4f2300029732","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"f45aa048-e0b1-55dc-9f40-68f5af6d3b61","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"1f101b12-c624-5d0c-9b55-c7fa2d40a3ed","slug":"mucolytics","fullItemName":"Mucolytics"},{"id":"669a5030-cc7b-5a64-ba03-f05ca2dd60f3","slug":"theophylline","fullItemName":"Theophylline"},{"id":"2006f9b1-cca0-50cd-9c1e-99a6316048e4","slug":"antibiotics","fullItemName":"Antibiotics"}]},{"id":"81fd9c2f-91c3-5726-b50a-85fc169646d3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6b91263e-7dc1-51aa-9976-bd92619d846e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ac29e092-9d36-550e-99e2-c6b478d21c00","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"737d1a20-607a-560b-8522-2ddb2237249b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bec938e3-108f-5f91-9c9b-2c289bae4e07","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"dc4c2f7c-85ce-5ba5-a2ef-149ee8a9d54d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"51ecdba0-ee93-5792-af12-b38cb8f06b8c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9ad1cd46-bf5b-505f-a6d9-bad7287adccc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2eb66d0c-0e3f-55c2-bb2f-ba47fdbd1bfd","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"c400b122-7978-522a-bdd7-639f11b7a86f","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 48098a9f-7f81-4ccf-8020-3f20152801d6 --><h3>Previous changes</h3><!-- end field 48098a9f-7f81-4ccf-8020-3f20152801d6 -->","summary":null,"htmlStringContent":"<!-- begin item 06871bb6-0530-45d3-9122-bc5dedd965ab --><!-- begin field 847220fa-0d0d-40ba-9df6-b96346cb9607 --><p><strong>August 2019</strong> — minor update. Topic updated in line with NICE chronic obstructive pulmonary disease in over 16s: diagnosis and management.</p><p><strong>March 2019</strong> — minor update. Acetylcysteine is now a licenced mucolytic for COPD, prescribing information has been updated accordingly.</p><p><strong>December 2018</strong> — minor update. Information added to acute exacerbation scenario to bring topic in line with NICE guideline Chronic obstructive pulmonary disorder (acute exacerbation): antimicrobial prescribing.</p><p><strong>May 2018</strong> — minor update. New product availability. Daxas (roflumilast) 250 micrograms tablets, new strength of tablet (previously only 500mg available). Roflumilast is licensed for maintenance treatment of severe COPD linked to chronic bronchitis in adults with a history of frequent exacerbations as add-on to bronchodilator treatment.</p><p><strong>December 2016</strong> — minor update. A metered-dose version of Symbicort® has been added to the available corticosteroids preparations section. Information that an increased risk of pneumonia has been observed in patients with COPD receiving inhaled corticosteroids, and that risk may be increased with increasing steroid dose, has been added to this topic.</p><p><strong>July to September 2015</strong> — reviewed. A literature search was conducted in July 2015 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone minor restructuring. No major changes to the recommendations have been made.</p><p><strong>July 2014</strong> — minor update. The text has been updated to replace the Liverpool Care Pathway with new standards of care that have been issued by the Leadership Alliance for the Care of Dying People (www.nhsiq.nhs.uk (pdf)).</p><p><strong>March 2014</strong> — minor update. Links to the European Committee for Standardization have been removed (www.cen.eu/) as this no longer has text on the use of nebulisers.</p><p><strong>July 2013 </strong>— minor update. Links to the DVLA website have been updated.</p><p><strong>June 2013</strong> — minor update. The 2013 QOF options for local implementation have been added to this topic.</p><p><strong>March 2012</strong> — minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012.</p><p><strong>February 2012</strong> — minor update. A recommendation to advise people inhaling terbutaline via a turbohaler to rinse their mouth after each use to minimize systemic adverse effects has been added, following an update to the manufacturer's Summary of Product Characteristics. Issued in March 2012.</p><p><strong>November 2011</strong> — minor update. The black triangle has been removed from Serevent Evohaler® (salmeterol CFC-free inhaler); prescriptions have been amended to reflect this. Issued in December 2011.</p><p><strong>September 2011</strong> — minor update. NICE has recommended in its COPD Quality Standard document that people receiving long-term oxygen therapy should have a review at least once a year, which includes pulse oximetry. Issued in October 2011.</p><p><strong>September 2011</strong> — minor update. Further evidence has been added from a recent systematic review and meta-analysis of randomized controlled trials which found that compared with placebo, Spiriva Respimat® 5 micrograms/day was associated with a statistically significant increased risk of mortality. Issued in October 2011.</p><p><strong>May 2011</strong> — minor update. The 2011/2012 QOF indicators have been added to this topic. Issued in June 2011.</p><p><strong>February 2011 </strong>— minor update. The range of long-acting beta-2 agonist inhaler devices included as prescriptions has been updated. Issued in February 2011.</p><p><strong>November 2010 </strong>— minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued advice that the Spiriva Respimat® formulation of tiotropium should be used with caution in people with known cardiac rhythm disorders. Issued in November 2010.</p><p><strong>July to November 2010 </strong>— topic updated. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>March 2010</strong> — minor update. All strengths of Beclazone® inhalers have been discontinued. Prescriptions removed. Issued in March 2010.</p><p><strong>January 2010</strong> — minor update to text regarding drug interactions with theophylline. Issued in January 2010.</p><p><strong>October 2009</strong> — minor typographical error corrected. Issued in October 2009.</p><p><strong>July 2009 </strong>— minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued advice on the use of long-acting beta-2 agonists and inhaled corticosteroids in COPD. Issued in July 2009.</p><p><strong>June 2009 </strong>— minor update. Broken link removed. Issued in June 2009.</p><p><strong>May 2009</strong> — minor update. A budesonide CFC-free pMDI has been launched, and a prescription has been added. The Nebuhaler® spacer device has been discontinued. This prescription has been replaced with the NebuChamber® spacer device. Issued in June 2009.</p><p><strong>April 2009</strong> — minor update. The Quality and Outcomes Framework (QOF) indicators for stopping smoking that apply to COPD have been added. Issued in May 2009.</p><p><strong>March 2009</strong> — minor update. The changes to the QOF for 2009/2010 for COPD have been updated in the Goals and outcome measures section. Issued in April 2009.</p><p><strong>May to August 2007</strong> — converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>April 2006</strong> — updated. Prescriptions for CFC-free and salmeterol pressurized metered-dose inhalers have replaced those for CFC-containing inhalers. Information on changing to CFC-free inhalers included in the Medicines management section. Issued in May 2006.</p><p><strong>January 2006</strong> — update to reflect the new supply arrangements for home oxygen. Oxygen prescriptions have been removed and changes to the text in management issues and the oxygen therapy scenario have been made. Volumatic® spacer device re-introduced and prescriptions included; terbutaline pressurized metered-dose inhalers have been discontinued and prescriptions removed. Issued in February 2006.</p><p><strong>October 2005</strong> — minor update. Volumatic® spacer device discontinued and prescriptions removed; advice for using alternative spacer devices included. Issued in November 2005.</p><p><strong>July 2005</strong> — updated to incorporate the Referral guidelines for suspected cancer published by the National Institute for Health and Care Excellence. Issued in July 2005.</p><p><strong>March 2004</strong> — reviewed. Validated in May 2004 and issued in July 2004.</p><p><strong>October 2000</strong> — reviewed and updated to incorporate recommendations from the Royal College of Physicians 1999 report on domiciliary oxygen therapy services. Validated in November 2000 and issued in October 2001.</p><p><strong>October 1997</strong> — rewritten. Replaces guidance on Chronic bronchitis, Emphysema and Acute exacerbation of COAD.</p><!-- end field 847220fa-0d0d-40ba-9df6-b96346cb9607 --><!-- end item 06871bb6-0530-45d3-9122-bc5dedd965ab -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}